论文部分内容阅读
乙型肝炎（HB）血源疫苗和酵母重组疫苗预防HB病毒（HBV）感染已获满意效果,然而,无应答或低应答现象不仅发生于肥胖、肾功能衰竭或免疫抑制者,亦可见于健康者,因此,有必要研制免疫原性较强的HB疫苗。目前使用的重组HB疫苗系S基因编码的226个氨基酸产物装配而成的抗原颗粒,由于前S基因编码的蛋白已结合在HBV包膜内,因此,前S基因产物至少在理论上可增强HB疫苗的保护作用。甲型肝炎（HA）灭活疫苗比目前使用的HB疫苗更有效,由SmithKline(SB)公司制备的HAVRIX标准剂量2针肌肉注射或较大剂量（HAVRIX 1440 ELISA单位/ml）1针注射即可提供保护水平抗体。因此,新型HA疫苗可能为重组或减毒活疫苗。另一种改进目前HA和HB疫苗的方法是制备联合疫苗。
Hepatitis B (HB) blood-borne vaccines and yeast recombinant vaccines have been shown to be effective in preventing HB virus (HBV) infection. However, no response or low response occurs not only in obesity, renal failure or immunosuppression, but also in health Therefore, it is necessary to develop a highly immunogenic HB vaccine. The recombinant HB vaccine currently in use is composed of 226 amino acid products encoded by the S gene. Since the protein encoded by the pre-S gene is already bound within the envelope of HBV, the pre-S gene product can at least theoretically enhance HB Vaccine protection. Hepatitis A (HA) inactivated vaccine is more effective than currently used HB vaccines, and HAVRIX standard dose 2-dose intramuscular or larger doses (HAVRIX 1440 ELISA units / ml) manufactured by SmithKline (SB) Provide protection level antibodies. Therefore, the new HA vaccine may be a recombinant or attenuated live vaccine. Another way to improve the current HA and HB vaccines is to prepare a combination vaccine.